UTH Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
UTH Stock 12 Month Forecast
Average Price Target
$547.49
| Highest Price Target$597.71 | Average Price Target$547.49 | Lowest Price Target$417.91 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
―
Buy
―
Reiterated
06/29/26
Morgan Stanley
CHF417.91
Hold
―
Reiterated
06/04/26
H.C. Wainwright
CHF534.54
Buy
―
Reiterated
05/29/26
Jefferies
CHF541.01→CHF593.66
Buy
―
Reiterated
05/19/26
Wells Fargo
CHF465.69→CHF597.71
Buy
―
Upgraded
05/07/26
RBC Capital
CHF572.6→CHF567.74
Buy
―
Reiterated
05/06/26
Raymond James
CHF566.93
Buy
―
Initiated
04/09/26
Bank of America Securities
CHF460.83→CHF507
Hold
―
Reiterated
03/30/26
Cantor Fitzgerald
CHF425.2→CHF506.19
Buy
―
Initiated
03/12/26
UBS
CHF530.49→CHF570.98
Buy
―
Assigned
03/05/26
Argus Research
CHF453.55
Buy
―
Assigned
03/03/26
BTIG
―
Hold
―
Reiterated
02/25/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
―
Buy
―
Reiterated
06/29/26
Morgan Stanley
CHF417.91
Hold
―
Reiterated
06/04/26
H.C. Wainwright
CHF534.54
Buy
―
Reiterated
05/29/26
Jefferies
CHF541.01→CHF593.66
Buy
―
Reiterated
05/19/26
Wells Fargo
CHF465.69→CHF597.71
Buy
―
Upgraded
05/07/26
RBC Capital
CHF572.6→CHF567.74
Buy
―
Reiterated
05/06/26
Raymond James
CHF566.93
Buy
―
Initiated
04/09/26
Bank of America Securities
CHF460.83→CHF507
Hold
―
Reiterated
03/30/26
Cantor Fitzgerald
CHF425.2→CHF506.19
Buy
―
Initiated
03/12/26
UBS
CHF530.49→CHF570.98
Buy
―
Assigned
03/05/26
Argus Research
CHF453.55
Buy
―
Assigned
03/03/26
BTIG
―
Hold
―
Reiterated
02/25/26
Best Analysts Covering United Therapeutics
3 Months
Success Rate
15/18 ratings generated profit
Average Return
+15.56%
Copying Roanna Ruiz's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +15.56% per trade.
1 Year
Success Rate
12/13 ratings generated profit
Average Return
+32.34%
Copying Roger Song's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +32.34% per trade.
2 Years
Success Rate
22/22 ratings generated profit
Average Return
+59.65%
Copying Jessica Fye's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +59.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
UTH Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
10
22
21
24
15
Hold
7
11
11
9
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
33
32
33
20
Each month's total comprises the sum of three months' worth of ratings.
UTH Financial Forecast
UTH Stock Forecast FAQ
What is CH:UTH’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics Corp.’s 12-month average price target is 547.49.
What is CH:UTH’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for CH:UTH, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is United Therapeutics Corp. a Buy, Sell or Hold?
United Therapeutics Corp. has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is United Therapeutics Corp.’s share price target?
The average share price target for United Therapeutics Corp. is 547.49. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $597.71 ,and the lowest forecast is $417.91. The average share price target represents N/A Increase from the current price of N/A.
The highest analyst share price target is $597.71 ,and the lowest forecast is $417.91. The average share price target represents N/A Increase from the current price of N/A.
What do analysts say about United Therapeutics Corp.?
United Therapeutics Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of United Therapeutics Corp.?
To buy shares of CH:UTH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.